Lucknow News Flash

(Albany, US) On October 13, 2026- DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the Pancreatic Ductal Adenocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Ductal Adenocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Pancreatic Ductal Adenocarcinoma Pipeline @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

• On October 7, 2026 – RenovoRx, Inc. announced that the first patient had been enrolled in the PRISM-TAMP investigator-initiated clinical trial, sponsored by the University of Vermont. The study is evaluating gemcitabine delivered through RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) platform before surgery in patients with borderline-resectable pancreatic ductal adenocarcinoma (PDAC). The trial aims to explore a targeted drug-delivery approach in a new treatment setting.
• On October 5, 2026 – Revolution Medicines, Inc. announced that the first patients had begun treatment in the Phase III RASolute 309 clinical trial, evaluating RASONQUE™ (daraxonrasib) in combination with zoldonrasib, an investigational RAS G12D-selective inhibitor, as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) with a RAS G12D mutation. The trial aims to evaluate a targeted combination approach against this aggressive form of pancreatic cancer.
• DelveInsight’s Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
• The leading Pancreatic Ductal Adenocarcinoma Companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics and others.
• Promising Pancreatic Ductal Adenocarcinoma Pipeline Therapies such as Chiauranib, Albumin-paclitaxel Injection, Gemcitabine Injection, Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Ductal Adenocarcinoma @ Pancreatic Ductal Adenocarcinoma Treatment Drugs

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. PDAC development is associated with a poor prognosis due to its complicated and multifactorial nature. There is a lack of simple, early detection methods and is typically diagnosed at a late stage because symptoms do not appear until the disease has progressed and metastasized to distinct sites. The major difficulties in treating pancreatic cancer lie at both the genetic and cellular levels. The extent of mutational changes in pancreatic tumors generates gene instability that appears to play an essential role in PDAC tumor growth and resistance to treatments.

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile

• Onvansertib: Cardiff Oncology

Onvansertib, an oral highly-selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC.

• Nadunolimab: Cantargia

Nadunolimab is a humanised monoclonal antibody lacking fucose, being developed by Cantargia, for the treatment of solid tumours, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Nadunolimab is a first-in-class anti-IL1RAP antibody, currently evaluated with standard of care chemotherapy or checkpoint inhibitor in five phase I/II clinical trials with a primary focus on PDAC and NSCLC. Nadunolimab induces ADCC and blocks signaling of both IL-1α and IL-1β, counteracting thecontribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy

• Zimberelimab: Arcus Biosciences

Zimberelimab is a monoclonal antibody that binds pd-1 restoring the antitumor activity of T-cells. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic. Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options. full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.

The Pancreatic Ductal Adenocarcinoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
• Pancreatic Ductal Adenocarcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market

Explore groundbreaking therapies and clinical trials in the Pancreatic Ductal Adenocarcinoma Pipeline @ New Pancreatic Ductal Adenocarcinoma Drugs

Pancreatic Ductal Adenocarcinoma Companies

Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics and others.

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Pancreatic Ductal Adenocarcinoma Treatment @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report

• Coverage- Global
• Pancreatic Ductal Adenocarcinoma Companies- Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics and others.
• Pancreatic Ductal Adenocarcinoma Pipeline Therapies- Chiauranib, Albumin-paclitaxel Injection, Gemcitabine Injection, Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin and others.
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Pancreatic Ductal Adenocarcinoma Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. NIS 793: XOMA
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CEND 1: Cend Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. DCC-3116: Deciphera Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. RMC-6236: REVOLUTION Medicines
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pancreatic Ductal Adenocarcinoma Key Companies
21. Pancreatic Ductal Adenocarcinoma Key Products
22. Pancreatic Ductal Adenocarcinoma Unmet Needs
23. Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers
24. Pancreatic Ductal Adenocarcinoma Future Perspectives and Conclusion
25. Pancreatic Ductal Adenocarcinoma Analyst Views
26. Pancreatic Ductal Adenocarcinoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight